Charles Schwab
TMCI icon

Charles Schwab’s Treace Medical Concepts TMCI Stock Holding History

Charles Schwab’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Sell
282,538
-46,301
-14% -$127K ﹤0.01% 2978
2026
Q1 		$441K Sell
328,839
-23,605
-7% -$47K ﹤0.01% 3141
2025
Q4 		$863K Sell
352,444
-62,562
-15% -$272K ﹤0.01% 2980
2025
Q3 		$2.78M Buy
415,006
+60,567
+17% +$395K ﹤0.01% 2670
2025
Q2 		$2.08M Sell
354,439
-25,972
-7% -$169K ﹤0.01% 2654
2025
Q1 		$3.19M Buy
380,411
+30,901
+9% +$278K ﹤0.01% 2459
2024
Q4 		$2.6M Sell
349,510
-41,523
-11% -$278K ﹤0.01% 2599
2024
Q3 		$2.27M Buy
391,033
+17,783
+5% +$114K ﹤0.01% 2667
2024
Q2 		$2.48M Buy
373,250
+14,900
+4% +$120K ﹤0.01% 2629
2024
Q1 		$4.68M Buy
358,350
+2,530
+0.7% +$33.7K ﹤0.01% 2311
2023
Q4 		$4.54M Buy
355,820
+19,571
+6% +$198K ﹤0.01% 2354
2023
Q3 		$4.41M Buy
336,249
+51,892
+18% +$950K ﹤0.01% 2312
2023
Q2 		$7.27M Buy
284,357
+21,119
+8% +$545K ﹤0.01% 2062
2023
Q1 		$6.63M Buy
263,238
+24,151
+10% +$567K ﹤0.01% 2066
2022
Q4 		$5.5M Buy
239,087
+5,208
+2% +$120K ﹤0.01% 2166
2022
Q3 		$5.16M Buy
233,879
+101,106
+76% +$1.96M ﹤0.01% 2204
2022
Q2 		$1.9M Buy
132,773
+7,052
+6% +$119K ﹤0.01% 2579
2022
Q1 		$2.38M Buy
125,721
+3,265
+3% +$63.5K ﹤0.01% 2586
2021
Q4 		$2.28M Buy
122,456
+41,867
+52% +$864K ﹤0.01% 2663
2021
Q3 		$2.17M Buy
80,589
+1,832
+2% +$50.4K ﹤0.01% 2684
2021
Q2 		$2.46M Buy
+78,757
New +$2.51M ﹤0.01% 2641

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab's TMCI Position: Q2 2026 in Review

Charles Schwab reduced its Treace Medical Concepts (TMCI) stake by 14% in Q2 2026, selling an estimated $127K and leaving 282,538 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Charles Schwab first reported a position in TMCI in Q2 2021 and has held it in 21 quarters since. The position peaked at $7.27M in Q2 2023. 117 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • Charles Schwab held 282,538 shares of Treace Medical Concepts worth $1.12M as of Q2 2026.
  • Charles Schwab sold 46,301 Treace Medical Concepts shares in Q2 2026, an estimated $127K.
  • Treace Medical Concepts made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2978 holding.
  • Charles Schwab first reported a position in Treace Medical Concepts in Q2 2021 and has held it in 21 quarters since.
  • Charles Schwab's Treace Medical Concepts position peaked at $7.27M in Q2 2023.
  • 117 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.